Long-term survival on imatinib for metastatic duodenal GIST: A case report
Author Information
Author(s): Sayantan Bhattacharya, Amit Kumar Choudhury, Ravi Srinivasan, John Morrissey, Mathew George
Primary Institution: George Eliot Hospital, Victoria Hospital, Warwick Medical School
Hypothesis
Can imatinib effectively control disease progression in advanced metastatic gastrointestinal stromal tumors?
Conclusion
Imatinib is a safe and effective drug for controlling disease progression in advanced metastatic GIST, significantly improving the patient's quality of life.
Supporting Evidence
- Imatinib was well-tolerated by the patient with stable disease.
- The patient maintained a WHO performance status of zero after treatment.
- CT scans showed no disease progression after six years of treatment.
Takeaway
A 68-year-old woman with a rare stomach tumor lived for six years without disease progression after starting a specific cancer drug called imatinib.
Methodology
The case report was prepared from medical records and radiology reports, detailing the patient's treatment and follow-up.
Limitations
The findings are based on a single case report, limiting generalizability.
Participant Demographics
A 68-year-old female patient.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website